Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7213350 | 0.86 | KMT2A (0.43) | KMT2ASMN1; SMN2HPGDL3MBTL1NPC1 | |
| SCHEMBL7213367 | 0.86 | KMT2A (0.43) | KMT2AMAPTSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL7219875 | 0.83 | KMT2A (0.41) | KMT2ASMN1; SMN2HPGDL3MBTL1NPC1 | |
| SCHEMBL7213372 | 0.82 | NPC1 (0.44) | KMT2AMAPTSMN1; SMN2HPGDNPC1 | |
| SCHEMBL7213373 | 0.76 | MAPK14 (0.36) | KMT2ASMN1; SMN2HPGDNPC1MEN1 | |
| SCHEMBL11711957 | 0.74 | PRKCG (0.50) | KMT2AMAPTPOLBSMN1; SMN2HPGD | |
| Methyl Benzoate SCHEMBL28309417 | 0.71 | TSHR (0.58) | KMT2ASMN1; SMN2HPGDMEN1KDM4E | |
| SCHEMBL5561237 | 0.69 | POLB (0.74) | KMT2AMAPTPOLBHPGDNPC1 | |
| SCHEMBL16583908 | 0.69 | NPC1 (0.63) | KMT2AMAPTSMN1; SMN2HPGDNPC1 | |
| SCHEMBL7219859 | 0.69 | HPGD (0.43) | KMT2AMAPTSMN1; SMN2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624309-B1 | Administering 4-heterocyclicbenzamide derivative | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | LLOYD JOHN (US) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | SCN1A, SCN1B, NR0B1 | KMT2A 2962/4885MAPT 4755/4885POLB 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.